Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinomarin is a line of 100% natural, hypertonic seawater nasal sprays developed by Gerolymatos International. The solution contains a higher concentration of mineral salts (2.3% NaCl) than the body's cells, which allows it to relieve nasal congestion through the natural process of osmosis. When applied to the nasal cavity, the hypertonic solution draws excess fluid out of the swollen nasal mucosa, thereby reducing edema, thinning mucus, and facilitating its removal. Sinomarin is indicated for the relief of nasal congestion associated with allergic rhinitis, the common cold, flu, and sinusitis. It is non-habit forming, free of preservatives and chemical additives, and does not cause the rebound congestion or drowsiness often associated with medicated decongestants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sinomarin.